Multiple Sclerosis and Neuroimmunology Clinical Trials

A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)
Sponsor: TG Therapeutics, Inc
NCT03277261
Ages Eligible for Study:  18 Years to 55 Years
Exclusions:

  • Treatment with prior Anti-CD20 or other B cell directed treatment
  • Treatment with the following therapies at any time prior to randomization: Alemtuzumab, Natalizumab, Teriflunomide, Leflunomide and Stem cell transplantation
  • Diagnosed with Primary Progressive MS (PPMS)

Study Active, Enrollment Open
PI: Christopher Lock
Yamuna Joseph, Clinical Research Coordinator
yamuna@stanford.edu

A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-Remitting Multiple Sclerosis (MNK14274069)
Sponsor: Mallinckrodt
NCT03126760
Ages Eligible: 18 Years and older
Exclusions:

  • History of use of Acthar for the treatment of multiple sclerosis (MS).
  • Previously treated with natalizumab, ocrelizumab, daclizumab or any immunosuppressants (including but not limited to cyclophosphamide, mitoxantrone, or rituximab) in the 6 months prior to the Screening Visit or throughout the study.
  • Any disease modifying treatments (including beta-interferons, glatiramer acetate, fingolimod, teriflunomide, and dimethyl fumarate) must have been on a stable dose(s) for 30 days prior to the Baseline Visit, and plan to remain on that dose(s) throughout the study.

Study Active, Enrollment Open
PI: Christopher Lock
Yamuna Joseph, Clinical Research Coordinator
yamuna@stanford.edu

An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis 

NCT02688985
Arm 4: RMS
 - delayed start, remain on current treatment for 3 months; inclusion requires one relapse in past year, or one Gd+ or new T2 lesion
Arm 5: PPMS
 - EDSS 3.0-6.5, CSF +ve for OCB or elevated IgG index
Exclusions: previous treatment with Tysabri, Lemtrada, Aubagio; treatment with Gilenya or Tecfidera within 6 months prior to enrollment
Study Active, Enrollment Closed
PI: Christopher Lock
Yamuna Joseph, Clinical Research Coordinator
yamuna@stanford.edu

A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
Sponsor: Novartis
NCT02792218
Study Active, Enrollment Closed
PI: Christopher Lock
Yamuna Joseph, Clinical Research Coordinator
yamuna@stanford.edu

Project BIG: The Stanford Brain Immune Gut Research Initiative
The purpose of this study is to collect biological samples to conduct research on inflammatory disorders affecting the nervous system with the goal of identifying biomarkers of disease.
NCT – N/A
IRB 36061
Ages Eligible: 18 Years and older
Study Active, Enrollment Open
PI: Jeffrey Dunn, MD 
Lila Perrone, Clinical Research Coordinator
perronel@stanford.edu

North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) Study
The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) is a national database that collects patient and physician-based information on MS and will bring together information and data collected in multiple registries and databases across the U.S. and Canada.
NCT – N/A
IRB: 36609
Sponsor: NARCRMS
Ages Eligible for Study:  18 Years to 50 Years
Study Active, Enrollment Open
PI: Jeffrey Dunn, MD 
Yamuna Joseph, Clinical Research Coordinator
yamuna@stanford.edu

Multicenter, Randomized, Double-Blind, Parallel-Group Extension to Study AC-058B201 to Investigate the Long-Term Safety, Tolerability, and Efficacy of 10, 20, and 40 mg/day ACT-128800, an Oral S1P1 Receptor Agonist, in Patients with Relapsing-Remitting Multiple Sclerosis 
NCT01093326
AC-058B202
Sponsor: Actelion Pharmaceuticals Ltd
Study Active, Enrollment Closed
PI: Jeffrey Dunn, MD 
Yamuna Joseph, Clinical Research Coordinator
yamuna@stanford.edu

A Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif ®) in Patients with Relapsing Multiple Sclerosis
NCT01412333
WA21093
Sponsor: Genentech
Study Active, Enrollment Closed
PI: Jeffrey Dunn, MD 
Yamuna Joseph, Clinical Research Coordinator
yamuna@stanford.edu

 

Neuroimmunology Clinical Trials Contact

Yamuna Joseph
Clinical Research Coordinator
Department of Neurosurgery and Neurology
Stanford University School of Medicine
Office: (650) 497-6810
Cell: (650) 529-5524
Fax: (650) 721-5113